---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: PD-1 inhibitor monotherapy"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: PD-1 inhibitor monotherapy. Topics: FDA-approved first-line indication: pembrolizumab as a single agent; KEYNOTE-048 design, stratification, and population; KEYNOTE-048 efficacy of pembrolizumab monotherapy at the interim analysis: CPS ≥1 and CPS ≥20 subgroups; KEYNOTE-048 pembrolizumab monotherapy: final analysis and the CPS 1-19 subgroup; 6 further topics. 10 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/pd-1-inhibitor-monotherapy"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: PD-1 inhibitor monotherapy

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 PD-1 Inhibitor Monotherapy

<a id="topic-2.2.2.1.1-1"></a>

### FDA-approved first-line indication: pembrolizumab as a single agent

> “KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-2"></a>

### KEYNOTE-048 design, stratification, and population

> “The efficacy of KEYTRUDA was investigated in KEYNOTE-048 (NCT02358031), a randomized, multicenter, open-label, active-controlled trial conducted in 882 patients with metastatic HNSCC who had not previously received systemic therapy for metastatic disease or with recurrent disease who were considered incurable by local therapies.”
> “Randomization was stratified by tumor PD-L1 expression (TPS ≥50% or <50%) according to the PD-L1 IHC 22C3 pharmDx assay, HPV status according to p16 IHC (positive or negative), and ECOG PS (0 vs. 1).”
> “A retrospective re-classification of patients’ tumor PD-L1 status according to CPS using the PD-L1 IHC 22C3 pharmDx assay was conducted using the tumor specimens used for randomization.”
> “The main efficacy outcome measures were OS and PFS as assessed by BICR according to RECIST v1.1 (modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ) sequentially tested in the subgroup of patients with CPS ≥20, the subgroup of patients with CPS ≥1, and the overall population.”
> “Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease (Stage IVA 19%, Stage IVB 6%, and Stage IVC 70%).”
> “Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-3"></a>

### KEYNOTE-048 efficacy of pembrolizumab monotherapy at the interim analysis: CPS ≥1 and CPS ≥20 subgroups

| Endpoint | CPS ≥1 | CPS ≥20 |
| --- | --- | --- |
| Participants, pembrolizumab 200 mg every 3 weeks | “n=257” | “n=133” |
| Participants, cetuximab with platinum and FU | “n=255” | “n=122” |
| Median OS, pembrolizumab, months (95% CI) | “12.3 (10.8, 14.9)” | “14.9 (11.6, 21.5)” |
| Median OS, cetuximab with platinum and FU, months (95% CI) | “10.3 (9.0, 11.5)” | “10.7 (8.8, 12.8)” |
| OS hazard ratio (95% CI) | “0.78 (0.64, 0.96)” | “0.61 (0.45, 0.83)” |
| Median PFS, pembrolizumab, months (95% CI) | “3.2 (2.2, 3.4)” | “3.4 (3.2, 3.8)” |
| Median PFS, cetuximab with platinum and FU, months (95% CI) | “5.0 (4.8, 5.8)” | “5.0 (4.8, 6.2)” |
| PFS hazard ratio (95% CI) | “1.15 (0.95, 1.38)” | “0.97 (0.74, 1.27)” |
| ORR, pembrolizumab (95% CI) | “19% (14.5, 24.4)” | “23% (16.4, 31.4)” |
| ORR, cetuximab with platinum and FU (95% CI) | “35% (29.1, 41.1)” | “36% (27.6, 45.3)” |
| Median duration of response, pembrolizumab, months (range) | “20.9 (1.5+, 34.8+)” | “20.9 (2.7, 34.8+)” |
| Median duration of response, cetuximab with platinum and FU, months (range) | “4.5 (1.2+, 28.6+)” | “4.2 (1.2+, 22.3+)” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-4"></a>

### KEYNOTE-048 pembrolizumab monotherapy: final analysis and the CPS 1-19 subgroup

> “At the time of the interim and final analyses, there was no significant difference in OS between the KEYTRUDA single agent arm and the control arm for the overall population.”
> “At the pre-specified final OS analysis comparing KEYTRUDA as a single agent to cetuximab in combination with chemotherapy, the hazard ratio for the subgroup of patients with CPS ≥1 was 0.74 (95% CI: 0.61, 0.90) and the hazard ratio for the subgroup of patients with CPS ≥20 was 0.58 (95% CI: 0.44, 0.78).”
> “In an exploratory subgroup analysis for patients with CPS 1-19 HNSCC at the time of the pre-specified final OS analysis, the median OS was 10.8 months (95% CI: 9.0, 12.6) for KEYTRUDA as a single agent and 10.1 months (95% CI: 8.7, 12.1) for cetuximab in combination with chemotherapy, with an HR of 0.86 (95% CI: 0.66, 1.12).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-5"></a>

### KEYNOTE-048 primary publication: pembrolizumab monotherapy overall survival

> “Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more.”
> “At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]).”
> “Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis.”
> “grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group”
> “pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.”

Source: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/)

<a id="topic-2.2.2.1.1-6"></a>

### KEYNOTE-048 four-year follow-up: pembrolizumab monotherapy

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).”
> “Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations (Data Supplement).”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”
> “A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.1-7"></a>

### KEYNOTE-048 five-year follow-up: pembrolizumab monotherapy

> “Median OS remained longer for pembrolizumab versus EXTREME in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20 (HR, 0.61; 95 % CI, 0.46-0.81) and CPS ≥ 1 populations (HR, 0.74; 95 % CI, 0.61-0.89), and similar in the total population (HR, 0.82; 95 % CI, 0.69-0.97).”
> “The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME”

Source: [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)

<a id="topic-2.2.2.1.1-8"></a>

### Pembrolizumab monotherapy by PD-L1 CPS subgroup: CPS 1-19 and CPS <1

> “For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).”
> “In the PD-L1 CPS < 1 subgroup, the ORR was 4.5% (n = 2; 95% CI, 0.6 to 15.5) for pembrolizumab versus 42.2% (n = 19; 95% CI, 27.7 to 57.8) for cetuximab-chemotherapy (Table 2 ).”
> “In the PD-L1 CPS 1-19 subgroup, the ORR was 14.5% (n = 18; 95% CI, 8.8 to 22.0) for pembrolizumab versus 33.8% (n = 45; 95% CI, 25.9 to 42.5) for cetuximab-chemotherapy (Table 2 ).”
> “Efficacy outcomes for the PD-L1 CPS < 1 and CPS 1-19 subgroups (OS, PFS, and ORR) were not prespecified.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-2.2.2.1.1-9"></a>

### Guideline recommendation: ASCO

> “Recommendation 2.1. Pembrolizumab monotherapy or pembrolizumab, platinum, and fluorouracil (5-FU) should be offered as first-line treatment for patients with recurrent or metastatic HNSCC with a CPS ≥ 1 (Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).”
> “Recommendation 1.2. PD-L1 CPS ≥ 1 should be interpreted as positive and correlates with a clinical benefit to PD-1 inhibitors (Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).”
> “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression,”
> “However, current data do not support changing recommendations for the addition or exclusion of anti–PD-1 therapies in the recurrent and/or metastatic setting with regard to the HPV status.”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.1-10"></a>

### Guideline recommendation: NCCN

> “The panel also considers pembrolizumab monotherapy as a preferred first-line option for patients with CPS ≥1 (category 1 if CPS ≥20).”

Source: [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
